The time to independence in ADLs is related to the baseline functioning, and therefore additional time of independence in ADLs attributable to DMT varies. For example, an individual with a baseline CDR‐SB of 2 (typically fully independent in BADLs, independent in IADLs but may have difficulty with remembering dates and medications) could expect around 10 additional months of independence in IADLs on lecanemab (95% CI 4–18 months) and 13 months of independence on donanemab (95% CI 6–24), assuming they have low/medium tau PET at baseline. In contrast, an individual with a baseline CDR‐SB of 3.5 (typically fully independent in BADLs, independent in IADLs but may have difficulty with remembering dates and medications, paying bills, and driving) could expect around 4 additional months of independence in IADLs on lecanemab (95% CI 2–7 months) and 5 months of independence on donanemab (95% CI 2–9 months) for those with low/medium tau PET. This interpretation of clinical meaningfulness of treatment will be particularly important for clinical decision‐making, allowing for personalized estimates of time to independence (based on baseline CDR‐SB and, potentially, tau PET levels) that can be weighed against an individual's risks of treatment.
